Raphaël Rousseau, Md, Phd Email & Phone Number

Los Altos, CA, US

Los Altos, CA, US

I am a clinical drug development consultant with over 25 years of hands-on experience designing and executing phase 1 to phase 4 clinical trials, across a wide array of therapeutics. I specialize in helping biopharmaceutical companies develop and implement a realistic clinical development plan based on unmet medical and market needs, with the "end in.

Brookline, Massachusetts, US

Paris, Île-de-France, FR

New York, NY, US

"Getting a taste of my own medicines" and experiencing the patient's side of things, ironically for an aggressive malignancy I know all too well as a trained hemato-oncologist and drug developer. I used to say I was "missing my time on the wards" since I joined biotech!A big thank you to the wonderful medical and nursing staff at Stanford Hospital's.

Brisbane, California, US

Brisbane, California, US

I joined Day One on a short-term mission to support the R&D organization's transition from late-stage clinical research to commercialization, its first BLA submission for tovorafenib in children with relapsed low-grade gliomas with BRAF alterations, the subsequent FDA review, and the organizational readiness for the US commercial launch.

Amsterdam, North Holland, NL

I joined Neogene post-Series B and prior to the first CTA & IND submissions. Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers. As the CMO, I was responsible for building the development team, leading.

Emeryville, California, US

I joined Gritstone post-Series A, built and led its development organization, and was responsible for the design and execution of the clinical development strategy in personalized and shared neoantigen therapeutic cancer vaccines (phase 1-2 and randomized phase 2-3 clinical trials). I was a member of the executive leadership team, participating in.

South San Francisco, California, US

I created and lead the innovative pediatric drug development group (iPODD, now a 60+ member team), oversaw Roche’s pediatric strategy and ensured optimized design & execution of pediatric investigational plans (phase 1 to phase 3 clinical trials) across the company’s oncology portfolio. I chaired the development review committee for all pediatric oncology.

Switzerland 🇨🇭, CH

Switzerland 🇨🇭, CH

I joined the Hematology Franchise Team (Basel) and was a member of the Rituxan®/MabThera® joint life cycle team (Genentech and Roche), which successfully launched a label extension in the EU and US for adult patients with newly diagnosed follicular lymphoma. I co-led the phase 4 program, which ultimately supported the launch of subcutaneous.

Villeurbanne, FR

tenured.I co-led the medical oncology curriculum for 3-4th year medical students and the launch of a new national medical school requirement for students to acquire proficiency in the critical analysis of peer-reviewed scientific publications.I launched a simulation-based learning approach for training medical students and residents in shared.

Houston, Texas, US

Lyon, FR

I joined Léon Bérard Comprehensive Cancer Center (CLB) as part of the merger between the pediatric oncology departments at CLB and Hospices Civils de Lyon, France. The Institute of Pediatric Hematology & Oncology (HOPE) was, at the time of its inception, the largest pediatric onco-hematology department in Europe. I was the group leader of the laboratory of.

Houston, TX, US

In parallel to my research fellowship, I obtained the United States Medical Licensure (USMLE) and the certification from the Educational Commission for Foreign Medical Graduates (ECFMG), and joined Texas Children's Cancer Center and Hematology Services (including bone marrow transplantation) as a clinical fellow.

Houston, Texas, US

At the Center for Cell and Gene Therapy, under the mentorship and supervision of Dr Malcolm Brenner, and with the support and collaboration of the CAGT team, I co-developed a translational, GMP-grade, FDA-approved antitumor approach using genetically modified autologous and allogeneic tumor cells to treat high-risk pediatric acute leukemias, chronic.

Paris, Île-de-France, FR

I trained in pediatrics, with a focus on pediatric intensive care, pediatric cardiology and pediatric hemato-oncology.I was elected chair of the Paris University Hospitals residents’ union (Syndicat des Internes des Hôpitaux de Paris, SIHP)

Clinical Fellow, Pediatric Hematology-Oncology

Habilitation À Diriger Des Recherches (Tenure), Therapeutic Biotechnologies

Phd (Docteur Ès Sciences), Therapeutic Biotechnologies

Pediatric Oncology Sub-Speciality (Diplôme Universitaire D'Oncologie Pédiatrique)

Pediatric Specialty (Diplôme D'Etudes Spécialisées En Pédiatrie)

Md (Docteur En Médecine), Medicine

Medical Ethics, Philosophy

Baccalaureate, Mathematics And Biological Sciences

Education record